Sign inJoin waitlistJoin the waitlist

Adil Daud

Clinical Professor · University of California (San Francisco) School of Medicine

Credentials: · · · · · · ·

History

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
1997–2000
Indiana University School of Medicine
1994–1997
Indiana University School of Medicine
1993–1994
Cleveland Clinic
1987–1989
Cleveland Clinic
1986–1989
MBBS, 12/1985 - Medicine, Government Medical College
1981–1985

Research

Pembrolizumab versus Ipilimumab in Advanced Melanoma
New England Journal of Medicine · 2015 · 4,750 citations
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
New England Journal of Medicine · 2013 · 2,799 citations
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
New England Journal of Medicine · 2012 · 2,234 citations

Omid Hamid
34 papers
Alain Algazi
33 papers · 4 as a fellow
Katy Tsai
27 papers · 10 as a fellow
Antoni Ribas
26 papers
Pamela Munster
25 papers
JW
Jeffrey Weber
20 papers
Stephen Hodi
18 papers
Michael Rosenblum
15 papers
Scot Ebbinghaus
15 papers
DS
Daniel Sullivan
13 papers
Nageatte Ibrahim
13 papers
Tara Mitchell
13 papers

Clinical trials

XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
Principal investigator · Terminated · Phase 1
University of California, San Francisco
2023–2024
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
Principal investigator · Completed
University of California, San Francisco
2021–2025
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
Principal investigator · Completed · Phase 2
University of California, San Francisco
2018–2022
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Principal investigator · Terminated · Phase 2
University of California, San Francisco
2015–2018